Reduced p27(Kip1) expression in hepatocellular carcinomas

Cancer Letters

Volumn 132, Issue 1-2, 1998, Pages 67-73

  Hui, Ai Min ^a   Sun, Lin ^a   Kanai, Yae ^a   Sakamoto, Michiie ^a   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cell cycle regulation; Cyclin dependent kinase inhibitor; Hepatocellular carcinoma; p27(Kip1)

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 0032561075     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00164-5     Document Type: Article

References (28)

1. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
2. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
3. DelSal G., Loda M., Pagano M. Cell cycle and cancer: critical events at the G1 restriction point. Crit. Rev. Oncogen. 7:1996;127-142.
4. Pardee A.B. G1 events and regulation of cell proliferation. Science. 246:1989;603-608.
5. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
6. Peter M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 79:1994;181-184.
7. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
8. INK4 in hepatocellular carcinoma. Hepatology. 24:1996;575-579.
9. WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology. 25:1997;575-579.
10. A.-M. Hui, M. Sakamoto, Y. Kanai, Y. Ino, M. Gotoh, S. Hirohashi, Cyclin-dependent kinase inhibitors and hepatocarcinogenesis, in: E. Tahara, K. Sugimachi, T. Oohara (Eds.), Recent Advances in Gastroenterological Carcinogenesis, Monduzzi Editore, Bologna, 1996, pp. 481-485.
11. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
12. Kip1, a cyclin-Cdk inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
13. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
14. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55:1995;1206-1210.
15. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55:1995;1211-1214.
16. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilczynski S., Lee Y.Y., Bartram C.R., Koeffler H.P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
17. Stegmaier K., Takeuchi S., Golub T.R., Bohhlander S.K., Bartram C.R., Koeffler H.P., Gilliland D.G. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res. 56:1996;1413-1417.
18. Kip1 in primary breast carcinomas. Hum. Genet. 97:1996;91-94.
19. Chomczynsky P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
20. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3:1997;227-230.
21. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature. 380:1996;262-265.
22. Kip1 by the human papillomavirus 16E7 oncoprotein. Oncogene. 13:1996;2323-2330.
23. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720.
24. Kip1. Cell. 85:1996;721-732.
25. Kip1-deficient mice. Cell. 85:1996;733-744.
26. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
27. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:1997;231-234.
28. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;6380-6385.